Physician
Gastroenterology
Dr. Albert J. Czaja, MD
|
|
Give Review
Albert J. Czaja, MD practices Gastroenterology. He graduated from Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School is ranked 1/12 in Research/PrimaryCare. He received awards:"Fellow (AGAF)". Albert Czaja is a published doctor and has 92 publications published. The lastest was: 'Validation of scoring system for diagnosis of autoimmune hepatitis.'
Publications
- Current and prospective pharmacotherapy for autoimmune hepatitis.
- Targeting Apoptosis in Autoimmune Hepatitis.
- Review article: chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets.
- Hepatic inflammation and progressive liver fibrosis in chronic liver disease.
- Review article: permanent drug withdrawal is desirable and achievable for autoimmune hepatitis.
- Review article: the prevention and reversal of hepatic fibrosis in autoimmune hepatitis.
- Letter: guidelines for the management of autoimmune hepatitis - author's reply.
- Letter: treatment of autoimmune acute liver failure--beyond consensus guidelines; author's reply.
- Cholestatic Phenotypes of Autoimmune Hepatitis.
- Review article: the management of autoimmune hepatitis beyond consensus guidelines.
- Current management strategies for hepatocellular carcinoma.
- Autoimmune hepatitis in diverse ethnic populations and geographical regions.
- Acute and acute severe (fulminant) autoimmune hepatitis.
- The overlap syndromes of autoimmune hepatitis.
- Hepatocellular Carcinoma and Other Malignancies in Autoimmune Hepatitis.
- Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part II.
- Nonstandard drugs and feasible new interventions for autoimmune hepatitis: part I.
- Drug choices in autoimmune hepatitis: Part B - nonsteroids.
- Drug choices in autoimmune hepatitis: Part A - steroids.
- Autoantibody-Negative Autoimmune Hepatitis.
- Emerging Treatments for Autoimmune Hepatitis.
- Cryptogenic Chronic Hepatitis and Its Changing Guise in Adults.
- Comparability of probable and definite autoimmune hepatitis by international diagnostic scoring criteria.
- Drug-induced autoimmune-like hepatitis.
- Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis.
- Performance parameters of the conventional serological markers for autoimmune hepatitis.
- Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis.
- Putting flesh and polish on autoimmune hepatitis and moving the disease of exclusion to inclusion.
- Autoantibodies as prognostic markers in autoimmune liver disease.
- Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis.
- Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal.
- Recurrent autoimmune hepatitis after liver transplantation: a disease continuum or a fresh start?
- Special clinical challenges in autoimmune hepatitis: the elderly, males, pregnancy, mild disease, fulminant onset, and nonwhite patients.
- Autoimmune liver disease.
- Performance parameters of the diagnostic scoring systems for autoimmune hepatitis.
- Frequency, behavior, and prognostic implications of antimitochondrial antibodies in type 1 autoimmune hepatitis.
- Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis.
- Successful endoscopic management of biliary cast syndrome in nonliver transplant patients.
- Genetic factors affecting the occurrence, clinical phenotype, and outcome of autoimmune hepatitis.
- Arthur Joseph McCullough, Jr., 58th President, AASLD.
- HLA DRB1*13 as a risk factor for type 1 autoimmune hepatitis in North American patients.
- HLA DQ gene dosage and risk and severity of celiac disease.
- Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease.
- Optimizing diagnosis from the medical liver biopsy.
- Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation.
- Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse.
- Autoimmune liver disease and rheumatic manifestations.
- Evidence of a genetic basis for the different geographic occurrences of liver/kidney microsomal antibody type 1 in hepatitis C.
- Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis.
- Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly.
- Autoimmune hepatitis--approach to diagnosis.
- Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease.
- Treatment challenges and investigational opportunities in autoimmune hepatitis.
- Autoantibodies in autoimmune liver disease.
- Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis.
- Frequency and significance of antibodies to Saccharomyces cerevisiae in autoimmune hepatitis.
- Autoantibodies in the diagnosis and management of liver disease.
- Frequency and significance of antibodies to chromatin in autoimmune hepatitis.
- Celiac disease-associated autoimmune cholangitis.
- Treatment of autoimmune hepatitis.
- Genetic bases of autoimmune hepatitis.
- Gender effects and synergisms with histocompatibility leukocyte antigens in type 1 autoimmune hepatitis.
- The role of histologic evaluation in the diagnosis and management of autoimmune hepatitis and its variants.
- Genetic effects on susceptibility, clinical expression, and treatment outcome of type 1 autoimmune hepatitis.
- Treatment strategies in autoimmune hepatitis.
- Autoimmune hepatitis after liver transplantation and other lessons of self-intolerance.
- Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis.
- Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis.
- Validation of scoring system for diagnosis of autoimmune hepatitis.
- Frequency and significance of antibodies to histones in autoimmune hepatitis.
- The nature and prognosis of severe cryptogenic chronic active hepatitis.
- Oral pulse prednisone therapy after relapse of severe autoimmune chronic active hepatitis. A prospective randomized treatment trial evaluating clinical, biochemical, a...
- Genetic predispositions for the immunological features of chronic active hepatitis.
- Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and...
- Chronic active hepatitis: the challenge for a new nomenclature.
- Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis.
- Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis in comparison with primary sclerosing cholangitis and autoimmune chronic activ...
- Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States.
- Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis.
- Significance of HLA DR4 in type 1 autoimmune hepatitis.
- Frequency and significance of antibodies to hepatitis C virus in polyarteritis nodosa.
- Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis.
- Portal hypertensive gastropathy: upper gastrointestinal X-ray appearance.
- Chronic graft-versus-host disease and primary biliary cirrhosis: sorting the puzzle pieces.
- The nature and prognostic implications of autoimmune hepatitis with an acute presentation.
- Autoimmune hepatitis. Evolving concepts and treatment strategies.
- Immunologic features and HLA associations in chronic viral hepatitis.
- Recent-onset autoimmune hepatitis. Biopsy findings and clinical correlations.
- High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis.
- The validity and importance of subtypes in autoimmune hepatitis: a point of view.
- Significance of human leukocyte antigens DR3 and DR4 in chronic viral hepatitis.
Schools
Harvard Medical School
Philadelphia General Hospital
Mayo Clinic Rochester
Doctors Specialties
- Gastroenterology
Accepted Insurances
Awards
- Fellow (AGAF)
Education
-
Mayo School of Graduate Medical Education -
Harvard Medical School
Hospital
-
Mayo Clinic - Rochester, Minnesota
Helpful Reviews
Similar Doctors
|
|
Dr. Stephanie L. Hansel, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William Sanchez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Barham K. Abu Dayyeh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Konstantinos N. Lazaridis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leila Neshatian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David H. Bruining, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amindra S. Arora, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sahil Khanna, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Camilleri, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert E. Sedlack, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elizabeth Coss, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dawn D. Ferguson, MD |